

Maklumat tambahan indikasi untuk upload pada laman web

Year 2013

Products Approved For Additional Indication (DCA 271 – 16 Disember 2013)

NO	PRODUCT (ACTIVE INGREDIENT)	ADDITIONAL INDICATION	MARKETING AUTHORIZATION HOLDER
1.	1.1 <b>VECTIBIX 100MG CONCENTRATE FOR SOLUTION FOR INFUSION</b> [Panitumumab 20mg/ml]	<p>➤ Indication:</p> <p><i>Vectibix is indicated for the treatment of adult patients with wild-type <b>RAS</b> metastatic colorectal cancer (mCRC):</i></p> <ul style="list-style-type: none"><li><i>• in first-line in combination with FOLFOX</i></li><li><i>• in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan)</i></li><li><i>• as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.</i></li></ul>	<b>GLAXOSMITHKLINE PHARMACEUTICAL SDN BHD</b> Level 6, Quill 9 112 Jalan Semangat 46300 Petaling Jaya, Selangor